FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial
October 12, 2018 at 12:48 PM EDT
CRISPR and Vertex were preparing to test the the ability of a new gene-editing technology, CRISPR/Cas9, in cutting out and replacing disease-causing snippets of DNA when the FDA placed the hold in May.
